Moderna to Build Vaccine Manufacturing Facility in Quebec
29 Abril 2022 - 12:06PM
Dow Jones News
By Michael Dabaie
Biotechnology company Moderna Inc. said it plans to build a mRNA
vaccine manufacturing facility in Quebec that will support a
long-term strategic partnership with the Canadian government to
enhance pandemic preparedness.
Once the facility is certified by Health Canada, the company
said it expects it to provide onshore respiratory vaccine
manufacturing capabilities and support future pandemic readiness.
The company said it sees the facility producing up to 100 million
mRNA respiratory vaccine doses annually.
The plans follow a memorandum of understanding between Moderna
and the Canadian government in August 2021.
Moderna expects the partnership to be finalized following
approval of the final agreement.
Once operational, the facility is expected to provide access to
a domestically manufactured portfolio of mRNA vaccines against
respiratory viruses, including Covid-19, seasonal influenza,
respiratory syncytial virus and other potential respiratory
viruses, Moderna said. In the event of a future pandemic, Moderna
said it expects that the facility could be activated on an urgent
basis to support Canada with direct access to rapid pandemic
response capabilities.
Moderna said it expects construction to start this year, with
the facility expected to become operational by the end of 2024.
The company's hares were up 2.6% to $146.32 in morning
trading.
On Thursday, Moderna said it submitted for emergency use
authorization from U.S. health regulators for its Covid-19 vaccine
in children 6 months to under 2 years and 2 years to under 6.
Write to Michael Dabaie at michael.dabaie@wsj.com
(END) Dow Jones Newswires
April 29, 2022 10:51 ET (14:51 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
Moderna (NASDAQ:MRNA)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Moderna (NASDAQ:MRNA)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024